US FDA’s Small Adcomm For Eisai/Biogen's Leqembi Suggests Gaps In Conflict-Of-Interest Screening

Late recusal of several potential panelists was the result of a recent docket submission containing a December research community letter signed by dozens of Alzheimer’s experts, FDA said; signatories included neurologist David Weisman, who had received a conflict-of-interest waiver that cited his role in a Phase II lecanemab study but not in an ongoing Phase III study.